
Pliant Therapeutics, Inc.: An In-Depth Look at the Company under Investigation
Investigation Launched Against Pliant Therapeutics, Inc. following Pausing of Clinical Trial On February 21, 2025, the law firm of Levi & Korsinsky announced that it has initiated an investigation into potential securities law violations by Pliant Therapeutics, Inc. (NASDAQ: PLRX) following the recent pause of the BEACON-IPF Phase 2b trial of the company’s lead drug,…